ERBB2 and non-small cell lung carcinoma: An increasing number of systemic treatment options are becoming available, including human epidermal growth factor receptor 2 (HER2)-targeted therapies and tyrosine kinase inhibitors for NSCLC with driver mutations; however, tumors without druggable mutations lack effective approaches, partially given the molecular divergence of primary tumors and BM, as well as the limitations caused by the blood-brain barrier (6).